585. Safety of Pfizer-BioNtech COVID-19 Vaccine in Healthcare Workers, Singapore

Abstract Background On 14 December 2020, the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine was granted emergency use authorization in Singapore. Healthcare workers (HCW) were prioritized to receive the vaccine. We aim to investigate the side effects and risk factors for allergic reactions in our institution. Methods All HCW vaccinations were recorded in an electronic centralized database. All reactions occurring within a 30-minute observation period post vaccination were recorded. Staff were required to report any vaccine-related medical consult including hospitalization occurring within 14 days after vaccination. Moderate/severe reactions were assessed by a medical team and determined if the reactions were probable allergic reactions with consultation with an Allergist. We extracted data from 8 Jan 2021 to 30 April 2021. Results 5030 and 159 HCW completed 2 doses and 1 dose of the vaccine respectively. There were 1056 HCWs (20.3%) with self-reported pre-existing allergy. There were 114 (1.1%) reactions occurring without the 30-minute observation period, and 64 (56.1%) were related to first dose of vaccine. The most common side effect experienced was aches or pain on any part of the body (n=46, 40.4%) followed by fatigue and/or giddiness (n=45, 39.5%), palpitations and/or shortness of breath (n=22, 19.3%), systemic rash and/or angioedema (n=12, 10.5%) and nausea and/or vomiting (n=12, 10.5%). A total of 23 HCWs complained of systemic rash and/or angioedema that occurred anytime post vaccination. Fifteen HCWs (0.29% of the cohort) were considered to have probable allergic reaction to the vaccine. None of the reactions were classified as anaphylaxis or severe reactions, but 4 HCWs required short hospitalization stay for observation. HCWs with pre-existing allergy had 2.6 times the risk of having probable vaccine-related allergic reaction than HCWs without pre-existing allergy (RR 2.6, 95% CI 0.9 to 7.3, p=0.068) but this was not statistically significant. Conclusion No anaphylaxis or severe reactions were observed in our institution. Acute side effects in our cohort were in line with published trial reports. We noted a raised relative risk of 2.6 of pre-existing allergy with probable vaccine-related allergic reaction but this was not statistically significant. Disclosures All Authors: No reported disclosures

Download Full-text

Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia

Pharmaceuticals ◽

10.3390/ph14090873 ◽

2021 ◽

Vol 14 (9) ◽

pp. 873

Author(s):

Abanoub Riad ◽

Barbora Hocková ◽

Lucia Kantorová ◽

Rastislav Slávik ◽

Lucia Spurná ◽

...

Keyword(s):

Side Effects ◽

Side Effect ◽

Healthcare Workers ◽

Large Scale ◽

Large Population ◽

Medical Attention ◽

Cross Sectional Survey ◽

Cross Sectional ◽

Post Vaccination ◽

Phase Iv

mRNA-based COVID-19 vaccines such as BNT162b2 have recently been a target of anti-vaccination campaigns due to their novelty in the healthcare industry; nevertheless, these vaccines have exhibited excellent results in terms of efficacy and safety. As a consequence, they acquired the first approvals from drug regulators and were deployed at a large scale among priority groups, including healthcare workers. This phase IV study was designed as a nationwide cross-sectional survey to evaluate the post-vaccination side effects among healthcare workers in Slovakia. The study used a validated self-administered questionnaire that inquired about participants’ demographic information, medical anamneses, COVID-19-related anamnesis, and local, systemic, oral, and skin-related side effects following receiving the BNT162b2 vaccine. A total of 522 participants were included in this study, of whom 77% were females, 55.7% were aged between 31 and 54 years, and 41.6% were from Banska Bystrica. Most of the participants (91.6%) reported at least one side effect. Injection site pain (85.2%) was the most common local side effect, while fatigue (54.2%), headache (34.3%), muscle pain (28.4%), and chills (26.4%) were the most common systemic side effects. The reported side effects were of a mild nature (99.6%) that did not require medical attention and a short duration, as most of them (90.4%) were resolved within three days. Females and young adults were more likely to report post-vaccination side effects; such a finding is also consistent with what was previously reported by other phase IV studies worldwide. The role of chronic illnesses and medical treatments in post-vaccination side effect incidence and intensity requires further robust investigation among large population groups.

Download Full-text

Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran

Scientific Reports ◽

10.1038/s41598-021-00963-7 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Farhang Babamahmoodi ◽

Majid Saeedi ◽

Reza Alizadeh-Navaei ◽

Akbar Hedayatizadeh-Omran ◽

Seyed Abbas Mousavi ◽

...

Keyword(s):

Side Effects ◽

Health Care Workers ◽

Healthcare Workers ◽

Neutralizing Antibody ◽

Detectable Level ◽

Common Side Effect ◽

Independent Evidence ◽

Randomized Controlled ◽

Care Workers ◽

The Mean

AbstractThe Sputnik V is a COVID- 19 vaccine developed by the Gamalia institute of epidemiology and microbiology and released on August 11, 2020. We provided independent evidence on side effects and immunogenicity following the administration of the Sputnik V COVID-19 in Iran. In this observational study, the healthcare workers who were vaccinated with the Sputnik V COVID-19 vaccine within February and April 2021 were evaluated. Among a total of 13,435 vaccinated healthcare workers, we received 3236 self-declaration reports of Sputnik V associated adverse events with the mean age 39.32 ± 10.19 years old which 38.8% were men and 61.2% were women. Totally 68.8% of females versus 66.2% of males reported side effects after receiving the first dose and 31.2% of females versus 33.8% of males reported side effects after the second dose of vaccine. The most common side effect was a pain in the injection site (56.9%), fatigue (50.9%), body pain (43.9%), headache (35.7%), fever (32.9%), joint pain (30.3%), chilling (29.8%) and drowsiness (20.3%). Side effects of the vaccine were significantly more frequent in females and younger individuals. Among a total of 238 participants, more than 90% after the first and second dose of vaccine had a detectable level of SARS-CoV-2 RBD antibody and SARS-CoV-2 neutralizing antibody. Although the overall rate of adverse effects was higher than the interim results from randomized controlled trials, our findings support the manufacturer’s reports about the high humoral immunogenicity of vaccine against COVID-19.

Download Full-text

Using qualitative data to examine disparities in cancer outcomes: Results from interviews with African American (AA) and white (W) patients regarding health beliefs and perceptions of chemotherapy

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.16016 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 16016-16016

Author(s):

B. N. Polite ◽

S. Gehlert ◽

F. Hlubocky ◽

D. Smith ◽

C. K. Daugherty

Keyword(s):

African American ◽

Side Effects ◽

Health Beliefs ◽

The Body ◽

Perceived Barriers ◽

Perceived Benefits ◽

Curative Intent ◽

Risks And Benefits ◽

To Receive

16016 Background: Prior data indicate African Americans are less likely to receive appropriate and timely therapy for breast, colon, and lung cancers. The reasons for this may involve differences in how AA patients (pts) perceive the risks and benefits of available therapies. In general, little is known about the beliefs of pts, and about AA’s in particular, toward the risks and benefits of chemotherapy. Methods: Semi-structured qualitative interviews are being conducted on pts who have been referred to receive chemotherapy for breast, colon, and lung cancer. Results: To date, 18 patients have been interviewed: 9AA, 9W; median age 61 (range 35–77); 11 lung, 4 breast, 3 colon (11 for adjuvant therapy and 7 with metastatic disease). Pts provided their beliefs on the role of chemotherapy. Many described the advantages of chemotherapy indicating the possibility of cure or remission. Others expressed a degree of skepticism about the curative intent of chemotherapy. Many indicated an expectation of moderate to severe side effects that may have lasting effects on the body. Trust in one’s physician and the role of religion/spirituality are also emerging themes. One AA pt described that chemotherapy was a way for physicians to experiment on patients. Others believed that trust in one’s physician was implicit and essential. Many indicated a belief in God but few believed that his/her religious beliefs affected his/her approach to treatment. Conclusions: Consistent with the health beliefs’ model, perceived benefits and perceived barriers (one’s belief about the tangible and psychological costs of the advised action) shape pts’ perceptions of chemotherapy. In this ongoing analysis, the perceived benefits are tempered by a degree of skepticism. The perceived barriers include concerns about the overall impact of chemotherapy on the body and spirit rather than specific short-term side effects. Also, belief in the use of chemotherapy as an experiment is potentially consistent with some African American patients’ perceptions. No significant financial relationships to disclose.

Download Full-text

POST COVID-19 VACCINATION SURVEY FROM MEDICAL PROFESSIONALS: A QUESTIONNAIRE BASED STUDY

10.36106/ijsr/9729433 ◽

2021 ◽

pp. 19-21

Author(s):

Reena Rani ◽

Shikha Saxena

Keyword(s):

Side Effects ◽

Vaccination Programme ◽

Medical Professionals ◽

Opinion Poll ◽

Post Vaccination ◽

Study Results ◽

The Government ◽

To Receive ◽

Vaccination Period

The seriousness of Covid-19 infection outbreak can be understood by looking at the Govt data or WHO data available. By analyzing the post vaccination experience from medical professionals we can use the data to further motivate general people to take the vaccine and shun the misconceptions and apprehensions related to the presently available vaccines .The objectives of the current study were to collect information about the perception of medical professionals on COVID-19 vaccine, to analyze the side effects in the rst 72 hours of post vaccination period and to associate the side effects with age, gender and presence of apprehensions. By taking the opinion poll and rating of the vaccine experience of medical professionals who are the rst ones on 1 – 10 Likert's scale we can bring out the true picture of their experience which can point towards the efciency of the Government vaccination programme and inspire more people to receive the vaccine in future to help prevent Covid-19 infection .Our study results can also validate the Govt. ofcial data of vaccination experience and satisfaction of people receiving it for the rst time and thereby making this drive a successful one.

Download Full-text

Healthcare Workers’ Willingness to Receive Influenza Vaccination in the Context of the COVID-19 Pandemic: A Survey in Southern Italy

Vaccines ◽

10.3390/vaccines9070766 ◽

2021 ◽

Vol 9 (7) ◽

pp. 766

Author(s):

Gabriella Di Giuseppe ◽

Concetta P. Pelullo ◽

Andrea Paolantonio ◽

Giorgia Della Polla ◽

Maria Pavia

Keyword(s):

Side Effects ◽

Influenza Vaccine ◽

Influenza Vaccination ◽

Healthcare Workers ◽

Southern Italy ◽

Hospitalized Patients ◽

Cross Sectional Survey ◽

Enabling Factors ◽

Cross Sectional ◽

To Receive

This cross-sectional survey was designed to evaluate hospital healthcare workers’ (HCWs) willingness to receive the influenza vaccination during the COVID-19 pandemic and to identify the related determinants, since it is plausible that the two epidemics will coexist in future winters. Overall, 68% out of 490 participants expressed their willingness to receive influenza vaccination in the 2020/21 season, with 95% of those ever and 45.8% of those never vaccinated in the previous six influenza seasons. Belief that influenza vaccine is useful in distinguishing influenza symptoms from those of COVID-19 and that the influenza vaccine is useful to prevent influenza in hospital settings, willingness to receive COVID-19 vaccination, having no concern about influenza vaccine side effects, concern about the possibility to transmit influenza to hospitalized patients, and influenza vaccination in previous years were all predictors of willingness to receive influenza vaccination. In the context of the COVID-19 pandemic, a relevant increase in the willingness to undergo influenza vaccination was reported. Therefore, interventions focused primarily on enabling factors are needed to promote the adherence to influenza vaccination in future seasons among HCWs.

Download Full-text

Kikuchi–Fujimoto Disease Post COVID-19 Vaccination: Case Report and Review of Literature

Vaccines ◽

10.3390/vaccines9111251 ◽

2021 ◽

Vol 9 (11) ◽

pp. 1251

Author(s):

Hui Min Tan ◽

Susan Swee-Shan Hue ◽

Aileen Wee ◽

Kay Choong See

Keyword(s):

Case Report ◽

Side Effects ◽

Literature Review ◽

Side Effect ◽

Clinical Course ◽

Rapid Development ◽

Asian Population ◽

Common Side Effect ◽

Review Of Literature ◽

Post Vaccination

With the rapid development of various coronavirus disease 2019 (COVID-19) vaccines in a bid to counter and contain the COVID-19 pandemic, unusual and uncommon side effects of COVID-19 vaccination have been increasingly reported in the literature. Ipsilateral lymphadenopathy is a fairly common side effect of vaccination of any kind, with its etiology most commonly related to reactive lymphadenopathy. However, Kikuchi–Fujimoto Disease (KFD) or necrotizing histiocytic lymphadenitis is rarely observed post-vaccination, with only one other case of KFD post COVID-19 vaccination reported to date. We report two more cases of KFD post COVID-19 vaccination in the Asian population, highlighting the clinical course and salient clinical, radiological and histologic findings. In addition, we provide a literature review of the existing cases of lymphadenopathy post COVID-19 vaccination with cytologic and/or histologic correlation.

Download Full-text

Effect of the third dose of BNT162b2 vaccine in quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare workers

10.1101/2021.10.20.21265269 ◽

2021 ◽

Author(s):

Maria Elena Romero-Ibarguengoitia ◽

Diego Rivera-Salinas ◽

Yodira Guadalupe Hernandez-Ruiz ◽

Ana Gabriela Armendariz-Vazquez ◽

Arnulfo Gonzalez-Cantu ◽

...

Keyword(s):

Side Effects ◽

Healthcare Workers ◽

Booster Dose ◽

Common Side Effect ◽

Igg Antibody ◽

Humoral Immune ◽

The Third ◽

Antibody Titers ◽

Original Scheme ◽

Prospective Longitudinal

Background: Vaccination is our main strategy to control SARS-CoV-2 infection. Given a decrease in the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers three months following the second BNT162b2 dose, healthcare workers got a third booster dose after six months of completing the original scheme. This study aimed to analyze quantitative SARS-CoV-2 spike 1-2 IgG antibody titers and safety of the third dose. Material and methods: A prospective longitudinal cohort study included healthcare workers who received a third booster dose after six months of the complete BNT162b2 regimen. We assessed the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers 21-28 days after the first and second dose, three months after the complete scheme, 1-7 days following the third dose, and 21-28 days after the boost. Results: The cohort comprised 168 non-immunocompromised participants of 41(10) years old, 67% being women. The third dose was associated with increasing the quantitative antibody titers, regardless of previous SARS-CoV-2 history. In negative SARS-CoV-2 history, the median (IQR) antibody titers increased from 379 (645.4) to 2960 (2010), while in positive SARS-CoV-2 history, from 590 (1262) to 3090 (2080). The third dose had less number of total side effects compared to the other two shots. The most common side effect after the third BNT162b2 shot was pain at the injection site (n=82, 84.5%), followed by tiredness (n=45, 46.4%), with a mild severity (n=36, 37.1%). Tiredness, myalgias, arthralgias, fever, and adenopathy were proportionally higher following the third dose than the two-dose regimen (p<0.05). Conclusion: The third dose applied after six months of the original BNT162b2 regimen provided a good humoral immune response by elevating the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers. The booster dose was well tolerated with no severe side effects after the additional BNT162b2 dose.

Download Full-text

Hormonal Link to Autoimmune Allergies

ISRN Allergy ◽

10.5402/2012/910437 ◽

2012 ◽

Vol 2012 ◽

pp. 1-5

Author(s):

Shilpa Shah

Keyword(s):

Menstrual Cycle ◽

Allergic Reaction ◽

Immune Reaction ◽

Allergic Inflammation ◽

Normal Function ◽

Allergen Exposure ◽

The Body ◽

Disproportionate Representation ◽

Allergic Reactions ◽

Cyclic Expression

IgE recognition of autoantigens might augment allergic inflammation in the absence of exogenous allergen exposure. Among allergy and autoimmunity, there is disproportionate representation of males before puberty and females after puberty, suggesting a role for sex hormones. Hormone allergy is an allergic reaction where the offending allergens are one's own hormones. It is an immune reaction to the hormones, which can interfere with the normal function of the hormones. It can occur perimenstrually in women along with the variation in menstrual cycle. The perimenstrual allergies are about the cyclic abundance of the hormone causing a cyclic expression of allergic symptoms. The inflammatory mechanisms of allergic reactions to hormone allergens, which are intrinsic to the body, are the same as the mechanisms of allergic reactions to external allergens.

Download Full-text

Breakthrough COVID-19 infection rate with Indian strain in Single-center Healthcare Workers: A real world data.

10.1101/2021.07.02.21258881 ◽

2021 ◽

Author(s):

RAVINDRA SABNIS ◽

Abhijit Patil ◽

Nitiraj Shete ◽

Arun Kumar Rastogi

Keyword(s):

Side Effects ◽

Infection Rate ◽

Healthcare Workers ◽

Breakthrough Infection ◽

Real World Data ◽

Post Vaccination ◽

Hospital Employees ◽

Indian Strain ◽

Care Workers ◽

Nih Classification

Abstract: Introduction: It is observed that many healthcare workers got COVID19 infection despite of completing both doses of Covishield vaccine. This study aimed to find real incidence of vaccine breakthrough infection. Material and methods: All hospital employees, who were fully vaccinated were included in study. Details about their vaccine side effects, infection prior to vaccination, post vaccination infection, severity of infection, hospital and ICU admission were noted. Results: None encountered any significant side effects of vaccine. Of the 461 participants, 86 (18.65%) got infection average 38 days (range 14 to 70days) after vaccination. As per the NIH classification, out of 86, disease was mild in 69(80.2%), moderate in 10(11.62%), severe in 6(6.97%) and critical in 1(1.16%). Of these, 10(11.62%) required hospital admission. Of these 10, 2 were shifted to ICU. Of the 2, One recovered while one died. Thus mortality was 1/86(1.6%). Conclusion: Breakthrough infection rate in health care workers was 18.65%. Moderate, severe or critical disease occurred in 19.7% participants even after two doses of vaccine. Mortality due to disease cannot be completely obviated due to vaccine. The vaccine was safe without any significant adverse events.

Download Full-text

The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19

Vaccines ◽

10.3390/vaccines9050502 ◽

2021 ◽

Vol 9 (5) ◽

pp. 502

Author(s):

Izabela Jęśkowiak ◽

Benita Wiatrak ◽

Patrycja Grosman-Dziewiszek ◽

Adam Szeląg

Keyword(s):

At Risk ◽

Side Effects ◽

High Risk ◽

Questionnaire Survey ◽

Healthcare Workers ◽

Statistical Data ◽

Vaccination Program ◽

Immunization Program ◽

Post Vaccination ◽

Anonymous Questionnaire

The pandemic of COVID-19 might be limited by vaccination. Society should be vaccinated to prevent the spread of coronavirus disease 2019 (COVID-19) and to protect persons who are at high risk for complications. In Poland, the National Vaccination Program has been introduced, which is a strategy for planning activities to ensure safe and effective vaccinations among Polish citizens. It includes not only the purchase of an appropriate number of vaccines, their distribution but also monitoring of the course and effectiveness of vaccination and the safety of Poles. The national COVID-19 immunization program has been divided into four stages. Stage 0 covers the healthcare workers to be vaccinated first, as they are most at risk of being infected with the coronavirus. The study aims to prove the thesis that GIS statistical data on the incidence of COVID-19 post-vaccination reactions should be verified, as patients do not report their occurrence through the procedure indicated by GIS. In March 2021, an anonymous questionnaire survey was conducted using an electronic questionnaire among persons belonging to group zero of the National Vaccination Program. The survey consisted of 19 short questions concerning, inter alia, getting COVID-19, post-vaccination reactions after receiving the first and second doses of the COVID-19 vaccine, and motivation to proceed with vaccination. A total of 1678 complete responses were received. It has been shown that only a small number of post-vaccination reactions are reported to the Sanitary Inspection, which makes GIS statistics on the incidence of post-vaccination reactions in COVID-19 unreliable. In addition, having earlier suffered from COVID-19 had an impact on the occurrence of more severe side effects after the first dose of the COVID-19 vaccine.

Download Full-text